Cellectis S.A. CLLS
1.03 USD -0.03 (-2.83%)
Regular-session close
1.03 0.00 0.00%
After hours · Nov 18, 4:00 PM ET
1.02 Day range 1.09
0.881 52-week range 5.45
- YTD
- -78.72%
- 1 year
- -74.94%
News
seekingalpha.com Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript
marketbeat.com What Cellectis (CLLS) Said on Its Q3 Earnings Call Cellectis NASDAQ: CLLS said its cash runway is expected to extend into the second half of 2028 once its planned restructuring is fully implemented, giving the gene editing company time to reach…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3…benzinga.com Update: Cellectis Q3 Adj. EPS $(0.59) Misses $(0.17) Estimate, Sales $5.439M Miss $15.615M Estimate Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.17) by 247.06 percent. This is a 3050 percent decrease over earnings of $0.02…
globenewswire.com Cellectis publie ses résultats financiers du troisième trimestre 2026 et une mise à jour de ses activités HEAL-101 a atteint jusqu'à 70 % d'édition in vivo d'APOC3, avec une activité limitée au foie, et a confirmé une réduction de 76 % des triglycérides dans des modèles murins (ESGCT 2026); lancement de…
globenewswire.com Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of…benzinga.com Cellectis Q3 EPS $(0.61) Misses $(0.17) Estimate, Sales $5.439M Miss $15.615M Estimate Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.17) by 258.82 percent. This is a 6200 percent decrease over earnings of $0.01…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Lisata Therapeutics (NASDAQ:LSTA) stock rose 37.2% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. BioStem Technologies…
globenewswire.com Cellectis to Report Third Quarter Financial Results on November 12, 2026 NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a genome engineering company developing genetic medicines for diseases that today demand…
globenewswire.com Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026 NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of…
globenewswire.com Cellectis présente de nouvelles données précliniques démontrant une édition efficace du gène APOC3 et une réduction marquée des triglycérides avec .HEAL-101 à l’ESGCT 2026 Un taux d'édition in vivo du gène APOC3 humain atteignant 70% après une seule administration Une réduction de 76 % du taux de triglycérides après une dose unique dans un modèle murin de la maladie…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to…
globenewswire.com Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Cellectis S.A. (“Cellectis”…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
globenewswire.com Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. BENSALEM, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
globenewswire.com Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) on behalf of investors…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to…
globenewswire.com Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
marketbeat.com Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders Cellectis NASDAQ: CLLS outlined plans to advance two preclinical in vivo gene-editing candidates for severe forms of dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia through…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
defenseworld.net Cellectis S.A. (NASDAQ:CLLS) Stock Has Consensus Price Target of $5.46 Cellectis S.A. (NASDAQ: CLLS - Get Free Report) has received an average rating of "Hold" from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment…
